Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/08/2022* -- Results Q3 2022 -- -0.72 --
11/08/2022* 16:30 EST Earnings Call Q3 2022 -- -- --
08/03/2022 -- Results Q2 2022 -0.57 -0.47 -21.28%
08/03/2022 16:30 EST Earnings Call Q2 2022 -- -- --
05/05/2022 -- Results Q1 2022 0.39 -0.45 186.2%
05/05/2022 16:30 EST Earnings Call Q1 2022 -- -- --
02/23/2022 -- Results Q4 2021 1.21 -0.32 481.1%
02/23/2022 16:30 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/08/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/03/2022
Beat/Miss Upgrade
Return Since -9.33%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
URL http://www.xencor.com
Investor Relations URL https://investors.xencor.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Nov. 08, 2022 (est.)
Last Earnings Release Aug. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-8.85%
80.03%
-16.72%
64.96%
-4.89%
26.87%
-8.04%
-33.18%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-21.90%
-87.17%
63.37%
16.67%
-79.93%
-17.17%
8.91%
-45.97%
-71.32%
-9.04%
-23.93%
70.05%
-17.52%
10.42%
-13.60%
-24.30%
-51.92%
-18.25%
-29.46%
-55.16%
-57.46%
-66.95%
321.7%
-47.71%
-67.81%
56.85%
-66.70%
-33.39%
-96.85%
-9.48%
-24.44%
-28.93%
-61.79%
As of October 04, 2022.

Profile

Edit
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
URL http://www.xencor.com
Investor Relations URL https://investors.xencor.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Nov. 08, 2022 (est.)
Last Earnings Release Aug. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
CNCR 761133.0 USD 3.71%
PBE 6.231M USD 2.60%
BGUIX 28848.00 USD 2.31%
PSCH 4.920M USD 1.50%
POAGX 105.88M USD 1.48%
F00000M14B 996268.0 USD 0.61%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter XNCR Tweets